Radiopharmaceutical therapy (RPT) offers molecular-targeted treatment strategies and presents an ideal model for advancing ...
The Food and Drug Administration (FDA) capped 2025 with a year-end report on Thursday, highlighting reforms, enforcement ...
Edge platforms, which provide a liaison between networks and legacy equipment, can provide a layer of cybersecurity ...
Here are 40 spine devices and technologies earning FDA clearances in 2025. Note: This is not an exhaustive list. 1. SurGenTec earned FDA 510(k) clearance for its OsteoFlo HydroFiber to be used as a ...
Abbott’s Volt pulsed field ablation system — for the treatment of atrial fibrillation. The Volt system delivers high-energy electrical pulses to targeted areas of the heart to disrupt abnormal rhythms ...
New Drug Application (NDA) submission on track for January 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in ...
To help protect yourself and your family from getting seriously ill, you may want to learn about additional vaccine options ...
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has completed the rolling submission of its Biologics License Application (BLA) ...
Background The landscape of tobacco and nicotine delivery products has rapidly evolved with the introduction of electronic ...
Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA-cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States.
The FDA issued an RFI seeking venture capital input on a new contract model to connect portfolio companies directly with ...
FDA approvals in 2025 introduced novel therapies and devices across ophthalmic subspecialties, emphasizing sustained efficacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback